Nitric oxide mediates caerulein-induced suppression of locomotor activity

Neuropeptides

Volumn 30, Issue 4, 1996, Pages 323-326

  Volke, V ^a   Soosaar, A ^a   Koks S ^a   Bourin, M ^b   Mannisto P T ^c   Vasar, E ^a  

^a UNIVERSITY OF TARTU   (Estonia)

^b UNIVERSITÉ DE NANTES   (France)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CERULETIDE; CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALIA; RODENTIA;

EID: 0029761083     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0143-4179(96)90020-7     Document Type: Article

References (17)

1. Antin J, Gibbs J, Holt J, Young RC, Smith GP. Cholecystokinin elicits the complete behavioral sequence of satiety in rats. J Comp Physiol Psychol 1975; 89: 784-790.
2. Poncelet M, Arnone M, Heaulme M et al. Neurobehavioral effects of SR 27897, a selective cholecystokinin type A (CCK-A) receptor antagonist. Naunyn-Schmiedeberg's Arch Pharmacol 1993; 348: 102-107.
3. Zetler G. Neuropharmacological profile of cholecystokinin-like peptides. Ann NY Acad Sci 1985; 448: 448-469.
4. O'Neill MF, Dourish CT, Iversen SD. Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCK-A receptor antagonist devazepide but not by the CCK-B recptor antagonist L-365, 260. Eur J Pharmacol 1991; 193: 203-208.
5. Soar J, Hewson G, Leighton GE, Hill RG, Hughes J. L364,718 antagonizes the cholecystokinin-induced supression of locomotor activity. Pharmacol Biochem Behav 1989; 33: 637-640.
6. Crawley JN, Hays SE, Paul SM. Vagotomy abolishes the inhibitory effect of cholecystokinin on rat exploratory behaviors. Eur J Pharmacol 1981; 73: 379-380.
7. Smith GP, Jerome C, Cushin BJ, Eterno R, Simansky KJ. Abdominal vagotomy blocks the satiety effect of cholecystokinin in the rat. Science 1981; 213: 1036-1037.
8. Ritter RC, Kalivas P, Bernier S. Cholecystokinin-induced supression of locomotion is attenuated in capsaicin pretreated rats. Peptides 1986; 7: 587-590.
9. Boulant J, Fioramonti J, Dapoigny M, Bommelaer G, Bueno L. Cholecystokinine and nitric oxide in transient lower esophageal sphincter relaxation to gastric distension in dogs. Gastroenterology 1994; 107: 1059-1066.
10. Stroff T, Lambrecht N, Peskar BM. Nitric oxide as mediator of the gastroprotection by cholecystokinin-8 and pentagastrin. Eur J Pharm 1994; 260: R1-R2.
11. Volke V, Kõks S, Vasar E, Bourin M, Bradwejn J, Männistö PT. Inhibition of nitric oxide synthase causes anxiolytic-like behaviour in an elevated plus-maze. Neuroreport 1995; 6: 1285-1288.
12. Brignola G, Calignano A, Di Rosa M. Modulation of morphine antinociception in the mouse by endogenous nitric oxide. Br J Pharmacol 1994; 113(4): 1372-1376.
13. Abekawa T, Ohmori T, Koyama T. Effect of NO synthase inhibition on behavioral changes induced by a single administration of metamphetamine. Brain Res 1994; 666: 147-150.
14. Bredt DS, Hwang PM, Snyder SH. Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature 1990; 347: 768-770.
15. Rees DD, Palmer RMJ, Schulz R, Hodson HF, Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. BrJ Pharmacol 1990; 101: 746-752.
16. L-NAME) of resistance of venous return in rats. Br J Pharmacol 1995; 114: 1454-1458.
17. Moore PK, Wallace P, Gaffen Z, Hart SL, Babbedge RC. Characterization of the novel nitric oxide synthase inhibitor 7-nitro indazole and related indazoles: antinociceptive and cardiovascular effects. Br J Pharmacol 1993; 110: 219-224.